620 related articles for article (PubMed ID: 18511928)
21. Cancer therapy: can the challenge be MET?
Corso S; Comoglio PM; Giordano S
Trends Mol Med; 2005 Jun; 11(6):284-92. PubMed ID: 15949770
[TBL] [Abstract][Full Text] [Related]
22. The function, proteolytic processing, and histopathology of Met in cancer.
Hanna JA; Bordeaux J; Rimm DL; Agarwal S
Adv Cancer Res; 2009; 103():1-23. PubMed ID: 19854350
[TBL] [Abstract][Full Text] [Related]
23. Autocrine and/or paracrine growth of aggressive ATLL cells caused by HGF and c-Met.
Onimaru Y; Tsukasaki K; Murata K; Imaizumi Y; Choi YL; Hasegawa H; Sugahara K; Yamada Y; Hayashi T; Nakashima M; Taguchi T; Mano H; Kamihira S; Tomonaga M
Int J Oncol; 2008 Oct; 33(4):697-703. PubMed ID: 18813782
[TBL] [Abstract][Full Text] [Related]
24. Invasive growth: a genetic program.
Gentile A; Comoglio PM
Int J Dev Biol; 2004; 48(5-6):451-6. PubMed ID: 15349819
[TBL] [Abstract][Full Text] [Related]
25. Gene of the month: MET.
Skead G; Govender D
J Clin Pathol; 2015 Jun; 68(6):405-9. PubMed ID: 25987653
[TBL] [Abstract][Full Text] [Related]
26. Caspase cleavage of the MET receptor generates an HGF interfering fragment.
Deheuninck J; Foveau B; Goormachtigh G; Leroy C; Ji Z; Tulasne D; Fafeur V
Biochem Biophys Res Commun; 2008 Mar; 367(3):573-7. PubMed ID: 18187039
[TBL] [Abstract][Full Text] [Related]
27. As we bring demethylating drugs to the clinic, we better know the DICE being cast.
Lizardi PM
Oncogene; 2010 Oct; 29(43):5772-4. PubMed ID: 20729909
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
29. The shadow of death on the MET tyrosine kinase receptor.
Tulasne D; Foveau B
Cell Death Differ; 2008 Mar; 15(3):427-34. PubMed ID: 17917681
[TBL] [Abstract][Full Text] [Related]
30. c-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice.
Giebeler A; Boekschoten MV; Klein C; Borowiak M; Birchmeier C; Gassler N; Wasmuth HE; Müller M; Trautwein C; Streetz KL
Gastroenterology; 2009 Jul; 137(1):297-308, 308.e1-4. PubMed ID: 19208365
[TBL] [Abstract][Full Text] [Related]
31. Flavonoids as RTK inhibitors and potential anticancer agents.
Teillet F; Boumendjel A; Boutonnat J; Ronot X
Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
Sadiq AA; Salgia R
J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S372-4. PubMed ID: 23160322
[No Abstract] [Full Text] [Related]
33. The multiple paths towards MET receptor addiction in cancer.
Duplaquet L; Kherrouche Z; Baldacci S; Jamme P; Cortot AB; Copin MC; Tulasne D
Oncogene; 2018 Jun; 37(24):3200-3215. PubMed ID: 29551767
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and biological evaluation of potent c-Met inhibitors.
D'Angelo ND; Bellon SF; Booker SK; Cheng Y; Coxon A; Dominguez C; Fellows I; Hoffman D; Hungate R; Kaplan-Lefko P; Lee MR; Li C; Liu L; Rainbeau E; Reider PJ; Rex K; Siegmund A; Sun Y; Tasker AS; Xi N; Xu S; Yang Y; Zhang Y; Burgess TL; Dussault I; Kim TS
J Med Chem; 2008 Sep; 51(18):5766-79. PubMed ID: 18763753
[TBL] [Abstract][Full Text] [Related]
35. Hgf/c-met expression and functional analysis during zebrafish embryogenesis.
Latimer AJ; Jessen JR
Dev Dyn; 2008 Dec; 237(12):3904-15. PubMed ID: 19035351
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in the discovery of small molecule c-Met Kinase inhibitors.
Parikh PK; Ghate MD
Eur J Med Chem; 2018 Jan; 143():1103-1138. PubMed ID: 29157685
[TBL] [Abstract][Full Text] [Related]
37. c-Met inhibition.
Salgia R
Clin Adv Hematol Oncol; 2006 Nov; 4(11):823-4. PubMed ID: 17143251
[No Abstract] [Full Text] [Related]
38. Development of c-MET pathway inhibitors.
Liu X; Newton RC; Scherle PA
Expert Opin Investig Drugs; 2011 Sep; 20(9):1225-41. PubMed ID: 21740293
[TBL] [Abstract][Full Text] [Related]
39. c-Met inhibitors with different binding modes: two is better than one.
Dussault I; Bellon SF
Cell Cycle; 2008 May; 7(9):1157-60. PubMed ID: 18418040
[TBL] [Abstract][Full Text] [Related]
40. Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF.
Zou JN; Wang SZ; Yang JS; Luo XG; Xie JH; Xi T
Cancer Lett; 2009 Jul; 280(1):78-85. PubMed ID: 19321255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
